Matinas BioPharma (MTNB) Stock Forecast & Price Target $2.95 -0.12 (-3.91%) (As of 10/3/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Matinas BioPharma - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating BuyBased on 1 Analyst RatingsSell0Hold0Buy1 Based on 1 Wall Street analysts who have issued ratings for Matinas BioPharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for MTNB. Consensus Price Target $3.001.69% Upside According to the 1 analysts' twelve-month price targets for Matinas BioPharma, the average price target is $3.00. The highest price target for MTNB is $3.00, while the lowest price target for MTNB is $3.00. The average price target represents a forecasted upside of 1.69% from the current price of $2.95. Get the Latest News and Ratings for MTNB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Matinas BioPharma and its competitors. Enter your email to sign up for newsletter Sign Up MTNB Analyst Ratings Over TimeTypeCurrent Forecast10/5/23 to 10/4/241 Month Ago9/5/23 to 9/4/243 Months Ago7/7/23 to 7/6/241 Year Ago10/5/22 to 10/5/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$3.00$3.00$3.00$3.00Forecasted Upside1.69% Upside1,515.51% Upside1,515.51% Upside733.33% UpsideConsensus RatingBuyBuyBuyBuy Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available on replay.Click here to watch it now. MTNB Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MTNB Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Matinas BioPharma Stock vs. The CompetitionTypeMatinas BioPharmaMedical CompaniesS&P 500Consensus Rating Score 3.00 2.78 2.50Consensus RatingBuyModerate BuyHoldPredicted Upside1.69% Upside850.31% Upside7.73% UpsideNews Sentiment RatingNeutral NewsSee Recent MTNB NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails10/11/2023BTIG Research2 of 5 stars Reiterated RatingBuy ➝ Buy$3.00+368.01%1/31/2023HC Wainwright2 of 5 stars Reiterated RatingBuy$3.00+420.37%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:52 AM ET. MTNB Forecast - Frequently Asked Questions What is Matinas BioPharma's forecast for 2024? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Matinas BioPharma is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. Should I buy or sell Matinas BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares. Does Matinas BioPharma's stock price have much upside? According to analysts, Matinas BioPharma's stock has a predicted upside of 1.69% based on their 12-month stock forecasts. Do Wall Street analysts like Matinas BioPharma more than its competitors? Analysts like Matinas BioPharma more than other "medical" companies. The consensus rating for Matinas BioPharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MTNB compares to other companies. Stock Forecasts and Research Tools Related Companies: CLRB Stock Forecast YS Stock Forecast ENTX Stock Forecast SLS Stock Forecast SPRO Stock Forecast ONCY Stock Forecast IOBT Stock Forecast CNTB Stock Forecast LPTX Stock Forecast OSTX Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…Go here to discover the coin that could define this historic bull run with gains kicking off this mo This page (NYSEAMERICAN:MTNB) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
